Evidence item

The excerpt directly reports the IMF6-high ARPI-versus-taxane hazard ratio, confidence interval, and P value. MEASUREMENT

Authenticity UNVERIFIED · extraction UNVERIFIED · independence group none (unreviewed) · created seq 15023

Source: Integrated signatures define mutational processes in prostate cancer · locator {} · excerpt hash sha256:34f904cccd56065c9facd1aa142c4d550fe17e8ee577208f452192a416ac7793

Exact excerpt

In patients predicted to be sensitive (IMF6 > median), ARPI treatment was associated with a significantly reduced risk of treatment failure compared to taxane (hazard ratio = 0.21, 95% confidence interval (CI) = 0.05–0.79, P = 0.021, Wald test), whereas no significant difference was observed among patients predicted to be resistant.

Linked claims

Claim	Direction	Relevance	Steps	Counted
3f2eb2a6	SUPPORT	DIRECT	0	yes

Audits

None.